Omisirge Approved for Patients With Blood Cancers to Reduce Infection Risk After Stem Cell Transplant

The FDA approved omidubicel-onlv (Omisirge, Gamida Cell), a substantially modified allogeneic (donor) cord blood-based cell therapy to quicken the recovery of neutrophils in the body and reduce the risk for infection. The product is intended for use in adults and pediatric patients 12 years of age and older with blood cancers planned for umbilical cord blood transplantation following a myeloablative conditioning regimen (treatment such as radiation or chemotherapy). 

Omidubicel-onlv,